Our top pick for
Inogen, Inc is a medical devices business based in the US. Inogen shares (INGN) are listed on the NASDAQ and all prices are listed in US Dollars. Inogen employs 1,020 staff and has a trailing 12-month revenue of around USD$313.4 million.
|52-week range||USD$26.57 - USD$56.46|
|50-day moving average||USD$49.9245|
|200-day moving average||USD$36.9534|
|Wall St. target price||USD$41.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.285|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Inogen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Inogen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Inogen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 99x. In other words, Inogen shares trade at around 99x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Inogen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.48. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Inogen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Inogen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$6.3 million.
The EBITDA is a measure of a Inogen's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$313.4 million|
|Gross profit TTM||USD$171.9 million|
|Return on assets TTM||-1.65%|
|Return on equity TTM||-0.6%|
|Market capitalisation||USD$1.1 billion|
TTM: trailing 12 months
There are currently 1.1 million Inogen shares held short by investors – that's known as Inogen's "short interest". This figure is 0.8% down from 1.1 million last month.
There are a few different ways that this level of interest in shorting Inogen shares can be evaluated.
Inogen's "short interest ratio" (SIR) is the quantity of Inogen shares currently shorted divided by the average quantity of Inogen shares traded daily (recently around 160040.36568214). Inogen's SIR currently stands at 7.11. In other words for every 100,000 Inogen shares traded daily on the market, roughly 7110 shares are currently held short.
However Inogen's short interest can also be evaluated against the total number of Inogen shares, or, against the total number of tradable Inogen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inogen's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Inogen shares in existence, roughly 50 shares are currently held short) or 0.119% of the tradable shares (for every 100,000 tradable Inogen shares, roughly 119 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Inogen.
Find out more about how you can short Inogen stock.
We're not expecting Inogen to pay a dividend over the next 12 months.
Over the last 12 months, Inogen's shares have ranged in value from as little as $26.57 up to $56.46. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inogen's is 0.9616. This would suggest that Inogen's shares are less volatile than average (for this exchange).
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.